May 2022 EMA meeting the CHMP recommended new indications for Cosentyx (juvenile PsA, Enthesitis-related arthritis), Olumiant (alopecia areata), Rinvoq (ulcerative colitis) and Xeljanz (ankylosing spondylitis). EMA approval pending https://t.co/KauDY6e8zS https://t.co/mmv4G9jHI7